Trial Profile
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Metformin
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 03 Mar 2021 Status changed from recruiting to completed.
- 15 Sep 2017 Results (n=60) assessing patients with type 2 diabetes without coronary artery disease, patients with type 2 diabetes and coronary heart disease and obese patients with abnormal oral glucose tolerance test (OGTT), changes in arterial stiffness, endothelial glycocalyx thickness and coronary reserve flow (CFR) after treatment with metformin or agonist GLP-1R, were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 10 Jan 2017 New trial record